Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
14.25
-0.43 (-2.93%)
Sep 15, 2025, 1:30 PM EDT - Market open
Pharming Group Revenue
Pharming Group had revenue of $93.22M in the quarter ending June 30, 2025, with 25.82% growth. This brings the company's revenue in the last twelve months to $339.84M, up 22.44% year-over-year. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue (ttm)
$339.84M
Revenue Growth
+22.44%
P/S Ratio
2.86
Revenue / Employee
$841,178
Employees
404
Market Cap
971.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PHAR News
- 5 days ago - Pharming Group promoted to the Euronext AMX® index - GlobeNewsWire
- 12 days ago - Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 13 days ago - Pharming Group appoints Kenneth Lynard as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Pharming Group to participate in August investor conference - GlobeNewsWire
- 6 weeks ago - Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Pharming Group reports second quarter and first half 2025 financial results and provides business update - GlobeNewsWire
- 2 months ago - Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31 - GlobeNewsWire
- 2 months ago - Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis - GlobeNewsWire